Hyper-IgM syndrome: genes and variants
Explore variant evidence for Hyper-IgM syndrome across 4 analyzed proteins (CD40LG, AICDA, CD40, UNG). Linked ClinVar records include 38 pathogenic or likely pathogenic variants, 215 variants of uncertain significance and 16 with conflicting classifications.
Coverage includes proteins already analyzed in CATVariant, not every gene involved in this condition. Database links are associations, not an assessment of clinical gene–disease validity. Computable evidence prioritizes variants for expert review and does not reclassify them. Source labels are pooled across this disease family.
Data updated 2026-11-05. Automated aggregation, not a clinical review date.
Download variant evidence (CSV)
Genes linked to Hyper-IgM syndrome
CD40LG: CD40 ligand
It is displayed by activated CD4 T cells and engages CD40 on B cells and antigen-presenting cells to drive class switching and effective adaptive immunity. Loss-of-function variants cause X-linked hyper-IgM syndrome, with impaired immunoglobulin class switching and opportunistic infections.
19 ClinVar pathogenic / likely pathogenic and 61 uncertain variants in CD40LG have source records linked to Hyper-IgM syndrome. Association strength is not clinical gene validity.
AICDA: Single-stranded DNA cytosine deaminase
It initiates somatic hypermutation and class-switch recombination in activated B cells by deaminating cytosines in immunoglobulin genes. Biallelic loss-of-function variants cause hyper-IgM syndrome type 2, with impaired antibody diversification and recurrent infections.
16 ClinVar pathogenic / likely pathogenic and 85 uncertain variants in AICDA have source records linked to Hyper-IgM syndrome. Association strength is not clinical gene validity.
CD40: Tumor necrosis factor receptor superfamily member 5
Its engagement on B cells and antigen-presenting cells promotes antibody class switching, germinal-center responses, and broader adaptive immune activation. Loss-of-function variants can cause hyper-IgM immunodeficiency, while excessive signaling contributes to autoimmunity and inflammation.
2 ClinVar pathogenic / likely pathogenic and 4 uncertain variants in CD40 have source records linked to Hyper-IgM syndrome. Association strength is not clinical gene validity.
UNG: Uracil-DNA glycosylase
It removes uracil from DNA and initiates base-excision repair, protecting the genome from cytosine deamination and misincorporated uracil. Biallelic loss-of-function variants can cause hyper-IgM syndrome through defective antibody class-switch recombination.
1 ClinVar pathogenic / likely pathogenic and 81 uncertain variants in UNG have source records linked to Hyper-IgM syndrome. Association strength is not clinical gene validity.
Where Hyper-IgM syndrome variants cluster
- CD40LG THD (positions 122–261): 17 of 19 ClinVar pathogenic / likely pathogenic variants, 1.7× more than its size predicts (a length-based count, not a validated hotspot).
ClinVar pathogenic and likely pathogenic variants linked to Hyper-IgM syndrome
| Variant | Position | Protein part | Clinical label |
|---|---|---|---|
| AICDA M139V | 139 | Pathogenic / likely pathogenic (★★) | |
| AICDA C87R | 87 | CMP/dCMP-type deaminase | Pathogenic / likely pathogenic (★★) |
| AICDA C87S | 87 | CMP/dCMP-type deaminase | Pathogenic / likely pathogenic (★★) |
| AICDA M139T | 139 | Pathogenic / likely pathogenic (★★) | |
| CD40LG T254M | 254 | THD | Pathogenic / likely pathogenic (★★) |
| AICDA R24W | 24 | CMP/dCMP-type deaminase | Pathogenic / likely pathogenic (★★) |
| CD40LG H125Y | 125 | THD | Pathogenic / likely pathogenic (★★) |
| AICDA Y31C | 31 | CMP/dCMP-type deaminase | Pathogenic / likely pathogenic (★★) |
| AICDA R112C | 112 | CMP/dCMP-type deaminase | Pathogenic / likely pathogenic (★★) |
| CD40LG M36R | 36 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| AICDA V57M | 57 | CMP/dCMP-type deaminase | Pathogenic / likely pathogenic (★★) |
| AICDA M139I | 139 | Pathogenic / likely pathogenic (★) | |
| CD40LG G257D | 257 | THD | Pathogenic / likely pathogenic (★) |
| CD40LG W140C | 140 | THD | Pathogenic / likely pathogenic (★) |
| CD40LG W140R | 140 | THD | Pathogenic / likely pathogenic (★) |
| CD40LG Y172H | 172 | THD | Pathogenic / likely pathogenic (★) |
| CD40LG Y172C | 172 | THD | Pathogenic / likely pathogenic (★) |
| CD40LG T254K | 254 | THD | Pathogenic / likely pathogenic (★) |
| CD40LG G257V | 257 | THD | Pathogenic / likely pathogenic (★) |
| AICDA L113P | 113 | CMP/dCMP-type deaminase | Pathogenic / likely pathogenic (★) |
| AICDA A111E | 111 | CMP/dCMP-type deaminase | Pathogenic / likely pathogenic (★) |
| CD40LG A123E | 123 | THD | Pathogenic / likely pathogenic (★) |
| CD40LG A141P | 141 | THD | Pathogenic / likely pathogenic (★) |
| CD40LG F229L | 229 | THD | Pathogenic / likely pathogenic (★) |
| AICDA L98R | 98 | CMP/dCMP-type deaminase | Pathogenic / likely pathogenic (★) |
| AICDA F15L | 15 | Bipartite nuclear localization signal | Pathogenic / likely pathogenic (★) |
| AICDA R24Q | 24 | CMP/dCMP-type deaminase | Pathogenic / likely pathogenic (★) |
| CD40LG G116C | 116 | Extracellular | Pathogenic / likely pathogenic (★) |
| CD40LG G167R | 167 | THD | Pathogenic / likely pathogenic (★) |
| CD40 E144K | 144 | TNFR-Cys 3 | Pathogenic / likely pathogenic (★) |
| CD40LG S128R | 128 | THD | Pathogenic / likely pathogenic |
| CD40LG G227V | 227 | THD | Pathogenic / likely pathogenic |
| AICDA L106P | 106 | CMP/dCMP-type deaminase | Pathogenic / likely pathogenic |
| AICDA F151S | 151 | Pathogenic / likely pathogenic | |
| CD40 C83R | 83 | TNFR-Cys 2 | Pathogenic / likely pathogenic |
| CD40LG A235P | 235 | THD | Pathogenic / likely pathogenic |
| UNG F251S | 251 | Pathogenic / likely pathogenic | |
| CD40LG E129G | 129 | THD | Pathogenic / likely pathogenic |
Uncertain variants prioritized for review in Hyper-IgM syndrome
| Variant | Position | Protein part | Clinical label | Evidence |
|---|---|---|---|---|
| AICDA C87G | 87 | CMP/dCMP-type deaminase | Conflicting reports (★) | +7: 2 other pathogenic changes within 3 positions; C87R at the same position is pathogenic; not seen in the gnomAD population database; REVEL 0.981 |
| CD40LG F229S | 229 | THD | Conflicting reports (★) | +6: 2 other pathogenic changes within 3 positions; F229L at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 0.92 |
| CD40LG Y172D | 172 | THD | Uncertain (★) | +6: 2 other pathogenic changes within 3 positions; Y172H at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 0.92 |
| CD40LG A123V | 123 | THD | Uncertain (★★) | +6: 2 other pathogenic changes within 3 positions; A123E at the same position is pathogenic; seen in 8.9e-06 of gnomAD DNA copies; REVEL 0.704 |
Which prediction tools work for Hyper-IgM syndrome
Observed separation of ClinVar pathogenic / likely pathogenic from benign / likely benign variants (AUROC × 100). This benchmark is not a clinical recommendation.
- PolyPhen-2: 99 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- CADD: 98 out of 100
- CATVariant: 98 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- AlphaMissense: 96 out of 100
- REVEL: 95 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- phyloP: 94 out of 100
- MutPred: 93 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- ESM1b (LLR): 91 out of 100
- MetaSVM: 90 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- SIFT: 89 out of 100
- MetaLR: 79 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- Pangolin: 49 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- SpliceAI: 44 out of 100 (learned from overlapping clinical labels, so this is optimistic)
Diseases related to Hyper-IgM syndrome
- Inflammatory bowel disease, also linked to CD40
Frequently asked questions
Which genes have records linked to Hyper-IgM syndrome?
This view contains 4 analyzed proteins: CD40LG, AICDA, CD40, UNG. Links come from clinical records and association databases. They do not imply that every listed gene is a validated cause, and missing genes may not yet be analyzed.
What do the clinical classifications mean?
Linked records include 38 pathogenic or likely pathogenic variants, 215 variants of uncertain significance and 16 with conflicting classifications. Labels summarize source records; multi-condition records may not make a separate assertion for this disease. Check the original record and review status.
Does the evidence score change a VUS classification?
No. 4 VUS or conflicting variants reach the likely-pathogenic points range on the computable criteria available here. This is a research prioritization signal, not a clinical classification. Patient, family and other required evidence may be missing.
Can I download the variant evidence?
Download the CSV for all 344 variants in the selected disease scope, including clinical labels, review status, evidence criteria, predictor scores, functional measurements and population frequency where available.
About this data
Variant–disease links come from ClinVar, Open Targets and UniProt, pooled from eligible public CATVariant analyses of each human protein. Evidence scores use the ACMG/AMP Bayesian points scale with computable criteria only (position among known disease variants, rarity in gnomAD, calibrated predictors, deep mutational scanning); there is no family or patient data, so they prioritise variants for expert review and never classify them.
Download every variant as CSV · Browse all diseases · Methods · About the Center